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Abstract
Despite the advent of new and aggressive therapeutics, breast cancer remains a leading killer among
women; hence there is a need for the prevention of this disease. Several naturally occurring
polyphenols have received much attention for their health benefits, including anti-carcinogenic
properties. Two of these are resveratrol, a component of red grapes, and epigallocatechin-3-gallate
(EGCG), the major catechin found in green tea. In this study, we tested the hypothesis that these
two polyphenols protect against chemically-induced mammary cancer by modulating mammary
gland architecture, cell proliferation, and apoptosis. Female Sprague-Dawley CD rats were exposed
to either resveratrol (1 g/kg AIN-76A diet), EGCG (0.065% in the drinking water), or control diet
(AIN-76A) for the entirety of their life starting at birth. At 50 days postpartum, rats were treated
with 60 mg dimethylbenz[a]anthracene (DMBA)/kg body weight to induce mammary cancer.
Resveratrol, but not EGCG, suppressed mammary carcinogenesis (fewer tumors per rat and longer
tumor latency). Analysis of mammary whole mounts from 50-day-old rats revealed that resveratrol,
but not EGCG, treatment resulted in more differentiated lobular structures. Bromodeoxyuridine
(BrdU) incorporation studies showed that resveratrol treatment caused a significant reduction in
proliferative cells in mammary terminal ductal structures at 50 days postpartum, making them less
susceptible to carcinogen insult. The epithelial cells of terminal end buds in the mammary glands of
resveratrol-treated rats also showed an increase in apoptotic cells compared to the control or
EGCG-treated rats as measured by a DNA fragmentation assay. At the given doses, resveratrol
treatment resulted in a serum resveratrol concentration of 2.00 μM, while treatment with EGCG
resulted in a serum EGCG concentration of 31.06 nM. 17β-Estradiol, progesterone, and prolactin
concentrations in the serum were not significantly affected by resveratrol or EGCG. Neither
polyphenol treatment resulted in toxicity as tested by alterations in body weights, diet and drink
consumptions, and day to vaginal opening. We conclude that resveratrol in the diet can reduce
susceptibility to mammary cancer, while EGCG in the drinking water at the dose used was not
effective.
Background
Breast cancer remains a leading killer among cancers that
affect women in the United States and around the world.
It was estimated that in 2005, in the US alone, there were
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211,240 new cases of female breast cancer and 40,410
deaths [1]. This remains a destructive disease despite the
advent of new and aggressive therapeutics. It is widely
accepted that environmental and dietary factors play a
role in determining one's risk of breast cancer. There is an
extensive and growing amount of work devoted to the
possible links between diet and a reduction in the risk of
breast cancer. Our lab has studied the effects of dietary
exposure to genistein, the primary isoflavone component
of soybeans. We have shown that genistein administered
in neonatal, prepubertal, and a combination of neonatal
and prepubertal periods followed by adult exposures can
suppress chemically-induced mammary cancer in
Sprague-Dawley rats [2-4]. Other dietary compounds that
have received much attention for their health benefits,
including anti-carcinogenic properties, are the naturally
occurring polyphenols resveratrol and EGCG.
Resveratrol is a polyphenolic phytoalexin present in grape
skins and red wine that has been shown to have antioxi-
dant and anti-inflammatory properties. In 1996, Jang et
al. reported that resveratrol could inhibit a number of cel-
lular events associated with the initiation, promotion, and
progression of cancer [5]. That report has been followed
with a battery of in vitro investigations into the chemopre-
ventive activity of resveratrol [6,7]. Also, there have been
reports in which resveratrol has been shown to reduce the
induction of chemically-induced breast cancer models.
Bhat et al. administered resveratrol via gavage and showed
an increase in tumor latency and a decrease in the total
number of tumors in an N-methyl-N-nitrosourea-(NMU)
induced mammary cancer model [8]. Dietary resveratrol
also reduced incidence and multiplicity and extended the
latency period in a DMBA-induced mammary cancer
model [9], although this study used a small number of
animals and what the authors called a DMBA dose "sub-
optimal to produce sufficient tumors". Our studyused die-
tary administration and employed at least 30 animals per
group and a dose of DMBA that was sufficient to cause
100% tumor incidence and resulted in an average of 8.5
tumors per rat in the control group.
The consumption of tea has been associated with a host of
health benefits including the prevention of cancer [10].
The chemopreventive effects of tea have been attributed to
the large amount of polyphenolic catechins present in tea.
A cup of tea contains 30–40% catechins by dry weight,
with EGCG being the most prevalent catechin [11]. These
catechins are strong antioxidants, have been associated
with a reduced risk of cardiovascular disease, and reported
to have anti-carcinogenic effects on skin, lung, oral cavity,
stomach, colon, pancreas, and breast cancers in animal
models [10]. Gupta et al. showed green tea polyphenols
can inhibit prostate tumors in a transgenic mouse model
[12].
To our knowledge, this is the first study that simultane-
ously investigated the potential of purified resveratrol and
chemically-synthesized EGCG throughout life in the diet
to suppress chemically-induced mammary cancer initi-
ated with concentrations of DMBA that result in adenocar-
cinomas. We also investigated the potential of resveratrol
or EGCG via the diet to modulate mammary gland matu-
ration, cell proliferation, and apoptosis in terminal mam-
mary structures as mechanisms for cancer
chemoprevention.
Methods
Animals
This study was approved by the University of Alabama at
Birmingham Animal Use Committee. Female Sprague-
Dawley CD rats (Charles River, Raleigh, NC) were housed
in a climate controlled room with a 12 hour light/dark
cycle (light on at 8:00 AM) in the UAB Animal Resources
Facility and fed phytoestrogen-free AIN-76A diet (Harlan
Teklad, Madison, WI). At birth, litters were placed on one
of three diets: 1) AIN-76A with tap water as the control, 2)
1 gram resveratrol/kg AIN-76A dietwith tap water, or 3)
0.065% EGCG in the drinking water with AIN-76A diet.
Resveratrol (Xi'an Sino-Dragon Import & Export Co.,
China) was extracted from Rhizoma Polygoni Cuspidati
and tested as 98% pure by HPLC. EGCG (a gift from
Roche Fine Chemicals, Basel, Switzerland) was chemi-
cally-synthesized at 93% purity as tested by HPLC. The
bottles used to administer all drinking fluids were an
amber color to suppress EGCG degradation. EGCG was
changed daily around 3 PM. Treatments were started at
birth and continued throughout the life of the animals,
with the rats having free access to both food and drink.
The resveratrol and EGCG doses were chosen based on
previous work by Bhat et al. and Gupta et al. [8,12]. Bhat
reported an inhibition of carcinogen-induced mammary
tumors by gavaging rats with 100 mg resveratrol/kg body
weight. Hence, we calculated that a 200 gram rat eating 20
grams of the provided diet with 1 mg resveratrol/g diet
would consume ~100 mg resveratrol/kg body weight.
Gupta showed a reduction in prostate tumors in the trans-
genic adenocarcinoma of the mouse prostate (TRAMP)
model using a 0.1% solution of green tea polyphenols
(62% of which was EGCG). Animals were weaned at 21
days postpartum. Body weights and food and drink con-
sumptions were measured at 21 and 50 days postpartum.
Onset of vaginal opening was recorded as a marker for
sexual maturity.
Tumor induction
At 50 days postpartum, 94 female rats (30 Control, 30 Re
sveratrol, and 34 EGCG) were gavaged with 60 mg
dimethylbenz[a]anthracene (DMBA)/kg body weight, a
dose sufficient to cause 100% tumor incidence in the con-
trol group over the course of the study. The DMBA wasJournal of Carcinogenesis 2006, 5:15 http://www.carcinogenesis.com/content/5/1/15
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dissolved in sesame oil at a stock solution of 30 mg/ml.
Animals were palpated twice a week starting five weeks
after DMBA administration in order to record the pres-
ence, location, size, and date of detection for all tumors.
Animals were sacrificed when the tumor diameter reached
one inch, animals became moribund, or rats reached 18
weeks post-DMBA treatment. Sections from the tumors
were fixed in 10% neutral buffered formalin and embed-
ded in paraffin. Tumor blocks were sectioned and fixed on
slides to be evaluated histopathologically by Dr. I.
Eltoum, a board certified pathologist at UAB.
Mammary gland differentiation
Whole mounts of the fourth abdominal mammary glands
were prepared from 50-day-old rats as previously
described [2]. Briefly, mammary glands were removed at
time of sacrifice and placed on a microscope slide. Glands
were fixed in neutral buffered formalin followed by de-fat-
ting in acetone. The glands were stained using 0.2% alum
carmine (Sigma, St. Louis, MO). Slides were dehydrated in
a series of graded alcohols from 35–100%. The slides were
cleared in xylene and compressed between two glass
slides. The glands were allowed to expand before being
mounted using glass coverslips. Glands were analyzed
using a Nikon light microscope (Nikon, Melville, NY) for
the quantity of terminal ductal structures including: end
buds, ducts, and lobules types I and II as previously
described [2,3,13]. A terminal end bud was characterized
as an elongated ductal structure with 3 to 6 epithelial cell
layers and >100 micrometers in diameter. Terminal ducts
have one to three epithelial cell layers and were <100
micrometers in diameter, while lobules I and II have 5–10
and 10–20 alveolar buds, respectively.
Cell proliferation
Bromodeoxyuridine (BrdU) (Sigma) incorporation was
used as an index of cell proliferation. BrdU was adminis-
tered two hours before sacrifice, injected i.p. with 100 mg
BrdU/kg body weight. The contralateral fourth mammary
gland was removed and fixed in 10% neutral buffered for-
malin. The glands were then placed in 70% ethanol over-
night before being embedded in paraffin. The blocks were
sectioned onto microscope slides. Slides were analyzed as
previously done in our lab [3]. Briefly, paraffin was
removed by xylene and the slides were rehydrated in eth-
anol. Slides were placed in 3.5 N HCl and then
trypsinized. Slides were placed in 3% H2O2 (Sigma) to
quench endogenous peroxidase and blocked in 10% nor-
mal horse serum (Vector, Burlingame, CA). Slides were
incubated with monoclonal anti-BrdU primary antibody
(Sigma) and subsequently incubated with biotinylated
horse anti-mouse secondary antibody (Vector). Detection
was performed using streptavidin (ABC reagent, Vector)
and the color developed by DAB (Vector). Slides were
counterstained with Gills no. 2 hematoxylin and then
dehydrated, cleared, and coverslipped. The labeling index,
which is the number of cells incorporating BrdU divid-
edby total number of cells × 100, was determined for ter-
minal end buds, terminal ducts, and lobules types I and II
using a Nikon light microscope and Nikon digital camera,
and analyzed using Image J software (NIH).
Apoptosis assay
The TdT-FragEL™ DNA Fragmentation Detection Kit (Cal-
biochem, San Diego, CA) was used to measure apoptosis
following the manufacturer's instructions. Briefly, paraf-
fin-embedded tissue sections were deparaffinized and
rehydrated in graded alcohols. Tissues were permeablized
with Proteinase K and rinsed with Tris-Buffered Saline.
Endogenous peroxidases were inactivated with 3% hydro-
gen peroxide and labeled with TdT enzyme. The labeling
reaction was terminated with Stop Buffer. The tissues were
blocked and then color detection was done with diami-
nobenzidine (DAB). The slides were couterstained with
methyl green, dehydrated in alcohol and xylene, and cov-
erslipped. The apoptotic index was the number of epithe-
lial cells stained positive for apoptosis divided by the total
number of epithelial cells counted in both mammary ter-
minal end buds and lobule structures. Visualization was
performed using a Nikon light microscope, Nikon digital
camera, and analyzed using Image J software (NIH).
Serum polyphenol concentrations
Blood was collected from 50 day old rats at the time of
sacrifice. Whole blood was spun at 2300 rpm for 15 min-
utes to collect serum and frozen at -80°C until use. Resver-
atrol and EGCG were extracted from the serum and
measured on a 4000 Q TRAP® LC/MS/MS System (Applied
Biosystems, Foster City, CA). Serum extractions were done
as previously described [[3] and [14]]. For resveratrol,
internal standards (apiginin, 4-methylumbelliferone, and
phenolphthalein glucuronide) were added to serum fol-
lowed by incubation with 1 mg β glucuronidase/sulfate
enzyme (Sigma) in 250 uL ammonium acetate buffer.
Samples were extracted in hexane and followed by ether
extraction. Samples were redissolved in 80% methanol
prior to LC/MS/MS analysis. For EGCG serum analysis,
1% acetic acid in 100% methanol was used after incuba-
tion with internal standards and β-glucuronidase enzyme.
A separate standard curve was run for each experiment.
Control serum was used as a negative control for both res-
veratrol and EGCG extractions.
Serum concentrations of 17β-estradiol, progesterone, and 
prolactin
Serum estradiol-17β, progesterone, and prolactin concen-
trations were measured using radio-immunoassays (Diag-
nostic Systems Laboratories, Webster, TX) as described by
the manufacturer. All samples were run in duplicate.Journal of Carcinogenesis 2006, 5:15 http://www.carcinogenesis.com/content/5/1/15
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Statistics
The time-to-event data, e.g., time-to-first-tumor (latency)
and time-to-sacrifice (tumor burden), were analyzed
using the LIFETEST and LIFEREG procedures in SAS® [15].
Survival functions were first estimated nonparametrically
using Kaplan-Meier (KM) and compared across the three
groups using the log-rank test and parametrically using
Weibull regression analysis. Those animals that did not
demonstrate the event in question by the end of study or
before sacrifice were treated as censored in the time-to-
event analysis and the end of study or sacrifice time sub-
stituted in for their actual times. Tumor multiplicity data
were analyzed with the GENMOD (generalized linear
models) procedure in SAS using generalized Poisson
regression on the tumor appearance rates (assuming a
negative binomial distribution). The rate of tumor
appearance was computed for each animal as the total
number of tumors divided by the number of days on the
study. For more detail about generalized linear models
and associated maximum likelihood estimation, see
McCullagh and Nelder [16]. All biochemical measure-
ments were done using Students t test with a p value of
0.05 as statistically significant, while group comparisons
were analyzed by one way analysis of variance (ANOVA)
in SAS.
Results
Body and uterine weights, and vaginal opening
Lifetime treatments with 1 g resveratrol/kg diet or 0.065%
EGCG in the drinking water did not result in a significant
difference in body weights as assessed at 21 or 50 days
postpartum (Table 1). Likewise, there was no difference in
the uterine/body weight ratio between the groups at ages
21 or 50 days. The average number of days to vaginal
opening, a marker for sexual maturation, was not altered
by resveratrol (34.95 ± 0.35) or EGCG (35.04 ± 0.35)
treatment as compared to the control rats (34.16 ± 0.40)
There were no observed differences in food or drink con-
sumption between the control and either polyphenol
treatment in 21, 35, 50, or 100 day old rats (data not
shown).
Tumor studies
Female Sprague-Dawley rats exposed to resveratrol in the
diet throughout life and to DMBA on day 50 postpartum
had significantly lower tumor multiplicity rates (Figure 1)
and significantly longer tumor latency (Figure 2A, B, and
2C) compared to control rats receiving DMBA. Animals
exposed throughout life to EGCG in the drinking water
showed a decrease in the latency to first tumor develop-
ment, although there was no significant difference as
compared to the control group with respect to second and
third tumor latency (Table 2A, B, and 2C). Likewise,
tumor multiplicity in EGCG-exposed rats was not signifi-
cantly different from the controls. Animals receiving res-
veratrol developed the lowest number of chemically-
induced mammary tumors per rat (4.39 ± 0.61) (Figure
1). This was a 50% reduction in the number of mammary
tumors compared to control animals (8.79 ± 1.33; p <
0.001). At the time of necropsy, animals that received
EGCG in the drinking water had fewer mammary tumors
per rat than the controls (6.74 ± 0.81 as compared to 8.79
± 1.33), but this did not reach statistical significance (p =
0.126) (Figure 1). Both resveratrol and EGCG had a signif-
icant influence on the latency of tumor development
(Table 2 and Figure 2A, B, and 2C). Rats exposed to resver-
atrol had a significantly delayed onset of the first mam-
mary tumor (76 days) as compared to the control animals
(57 days; p < 0.05). Animals exposed to EGCG had a
slight, but significantly enhanced onset of the first mam-
mary tumor (51 days) compared to control rats (57 days;
p < 0.05). This trend of delayed time to tumor develop-
ment continued for the second and third times to tumor
development in the resveratrol-treated rats, while the ani-
mals treated with EGCG were not significantly different
than the control group (Table 2). Neither EGCG nor res-
veratrol had an effect on mammary tumor incidence as
almost every animal (93 out of 94) developed at least one
tumor by the end of the study. One resveratrol-treated ani-
mal did not develop any tumors. All histologically evalu-
ated tumors were found to be adenocarcinomas. These
results demonstrated that treatment of resveratrol in the
diet significantly reduced the number and increased the
time to onset of DMBA-induced mammary tumors. EGCG
treatment showed no significant difference in the number
Table 1: Body weights and uterine to body weight ratios for female rats exposed to resveratrol or EGCG.
Treatment Age Body Weight (g) Uterine: BW Ratio
Control 21 Day 53.30 ± 1.09 0.57 ± 0.02
Resveratrol 21 Day 53.45 ± 1.25 0.56 ± 0.03
EGCG 21 Day 53.80 ± 0.67 0.53 ± 0.03
Control 50 Day 186.29 ± 3.25 1.79 ± 0.12
Resveratrol 50 Day 183.45 ± 2.84 1.95 ± 0.10
EGCG 50 Day 190.80 ± 2.63 1.54 ± 0.08
Female offspring of Sprague-Dawley CD rats were exposed to resveratrol (1 g/kg AIN-76A diet), EGCG (0.065% in drinking water), or AIN-76A 
alone as the control diet from birth to either 21 or 50 days postpartum. Values represent means ± SEM.Journal of Carcinogenesis 2006, 5:15 http://www.carcinogenesis.com/content/5/1/15
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of mammary tumors per rat compared to the control ani-
mals.
Mammary gland differentiation, cell proliferation, and 
apoptosis
The predominant mammary terminal ductal structures
found in 50-day-old control rats were terminal end buds
(37%), terminal ducts (31%), lobules type I (23%), and
lobules type II (9%). While resveratrol in the diet did not
significantly alter the numbers of individual structures,
the combined lobules types I and II were significantly
increased compared to the control group (Table 3). On
the other hand, EGCG in the diet significantly decreased
the number of terminal ducts but did not affect terminal
end buds, lobules I or lobules II.
BrdU incorporation was used as an index of cell prolifera-
tion. In the mammary glands of 50-day-old control rats,
the labeling indices were ~5% in terminal end buds and
terminal ducts and ~2% in lobules type I. Treatment with
resveratrol in the diet significantly reduced cell prolifera-
tion in all of the terminal ductal structures that were meas-
ured (terminal ducts, terminal end buds, and lobules I)
(Table 4). EGCG treatment did not alter the proliferation
indices for any of the mammary terminal ductal structures
as compared to the control group.
A DNA fragmentation assay was used to measure apopto-
sis. An apoptotic index was determined for mammary ter-
minal end buds and lobules (combined type I and II)
from 50-day-old rats. Rats treated with resveratrol showed
a significant increase in apoptotic index in the mammary
epithelial cells in terminal end buds as compared to the
control rats (Table 5). EGCG in the diet did not have an
effect on apoptosis in the epithelial cells of terminal end
buds as compared to the controls. Neither treatment
affected the apoptotic index in mammary lobules.
Serum polyphenol, 17β-estradiol, progesterone, and 
prolactin concentrations
Resveratrol and EGCG concentrations were measured in
the serum of 50-day-old animals. In the serum of rats
exposed to resveratrol in the diet, total resveratrol concen-
tration was 2.00 ± 0.64 μM. In the serum of the EGCG
treated group, at 50 days of age, the average concentration
of total EGCG was 31.06 ± 3.05 nM. All rats on the control
diet (AIN-76A) had non-measurable serum concentra-
tions of resveratrol or EGCG.
The concentrations of 17β-estradiol, progesterone, and
prolactin were measured in the serum of 50-day-old rats
treated with resveratrol or EGCG in the diet or drinking
water respectively (Table 6). There were no statistical dif-
ferences in serum estradiol levels between control (11.39
± 4.56 pg/ml), resveratrol-treated (13.87 ± 2.28 pg/ml), or
EGCG-treated rats (5.90 ± 1.64 pg/ml). Likewise, serum
progesterone concentrations were not altered by resvera-
trol (14.98 ± 2.73 ng/ml) or EGCG treatment (9.64 ± 1.45
ng/ml) as compared to the control rats (12.42 ± 2.70 ng/
ml). Neither resveratrol nor EGCG treatment affected
serum prolactin concentrations as compared to the con-
trols (1.24 ± 0.06, 1.19 ± 0.04, and 1.25 ± 0.10 respec-
tively).
Discussion
Body and uterine weights and vaginal opening
Resveratrol and EGCG given throughout life at concentra-
tions of 1 g resveratrol/kg diet and 65 mg EGCG/100 mL
water, respectively did not cause any significant altera-
tions on body or uterine weights in 21- and 50-day-old
female Sprague-Dawley rats. Dietary treatment through-
out life encompasses lactational exposure until time of
weaning at day 21 postpartum, plus eating and drinking
on their own after day 14. The number of days until vagi-
nal opening, a marker for sexual maturation, was meas-
ured with no significant difference between any of the
groups. Resveratrol and EGCG at the given concentrations
did not cause toxicity as observed by loss of weight or dif-
ferences in food and drink consumption. The lack of alter-
ation of body weights was expected as Juan et al. showed
that daily administration of resveratrol (20 mg/kg) had no
effect on final body weights or on the tissue weights of the
lungs, heart, liver, kidney, or adrenal glands [17]. Like-
wise, Hirose et al. showed no differences in body, liver, or
kidney weights after treatment with green tea catechins in
the diet or in the water [18].
Chemoprevention
Resveratrol given throughout life in the diet resulted in a
suppression of DMBA-induced mammary cancer. Rats
exposed to resveratrol had significantly fewer tumors per
animal compared to those that were not exposed to resver-
atrol, and the latency (time to first, second and third
tumors) was also significantly extended in the animals
exposed to resveratrol. The effect of increasing tumor
latency became more pronounced with each tumor. The
chemoprotective effect of resveratrol on the mammary
gland supports previous reports that resveratrol can sup-
press chemically-induced mammary carcinogenesis. Bhat
et al. showed protection with resveratrol via gavage against
NMU-induced mammary cancer, while Banerjee et al.
showed protection against DMBA-induced mammary
tumorigenesis [8,9], although the latter study was con-
ducted with a small number of animals and used a subop-
timal dose of DMBA which resulted in less than 80%
tumor incidence in the control group and fewer than 2.5
tumors per rat. We chose to use a statistically more robust
30 animals per group and a dose of DMBA that resulted in
100% incidence of mammary adenocarcinomas in the
control group over the course of the experiment, with anJournal of Carcinogenesis 2006, 5:15 http://www.carcinogenesis.com/content/5/1/15
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average of more than 8 tumors per rat in the control
group. All tumors examined histologically were deter-
mined to be adenocarcinomas.
Exposure to 0.065% EGCG in the drinking water,
throughout life, failed to protect the mammary gland
against DMBA-induced mammary cancer. As mentioned
above, the dose of EGCG was equivalent to one that
inhibited prostate tumors in the TRAMP model with green
tea polyphenol extract [12]. The tumor multiplicity in the
EGCG-treated group was not significantly different from
the animals that did not receive EGCG. While the time-to-
first tumor latency was slightly (yet significantly) shorter
than that of the control animals, the times-to-second and
-third tumors did not differ from that of the controls. We
interrupt this to mean that pure EGCG, at the given dose,
did not increase or decrease chemically-induced mam-
mary cancer. Not finding a chemopreventive effect using
EGCG is in line with several reports that show EGCG and
green tea as having minimal effects on mammary carcino-
genesis. Hirose et al. showed that a green tea polyphenol
fraction had no effect on tumor incidence or multiplicity
in a DMBA-induced mammary cancer model [18,19]. This
lack of effect could be due to several factors, including the
low reported bioavailability of EGCG [20]. Interestingly,
Chen et al. reported that rats receiving decaffeinated green
tea displayed a higher plasma concentration of EGCG
than rats receiving pure EGCG, even though the dose of
pure EGCG was five times higher [21]. This could impli-
cate the other catechins found in green tea as playing a
role in the bioavailability of EGCG and possibly the mam-
mary-protective effects using whole green tea polyphenols
or a mixture of green tea catechins [22,23]. It is important
to study whether EGCG is the most active player in green
tea or whether it is the mixture of catechins that is impor-
tant for the health related effects.
Mammary gland differentiation
The effects of resveratrol and EGCG as given through the
diet and drinking water, respectively were evident by the
changes in the number and distribution of the types of
mammary terminal ductal structures. At 50 days post-par-
tum, the time of carcinogen exposure, there was no statis-
tical difference in the numbers of terminal end buds
between any of the groups. Terminal end buds are the
Table 2: Tumor latency to first, second and third tumor development.
Treatment Median Time to First Tumor p value
Control 57 days -
Resveratrol 76 days 0.029
EGCG 51 days 0.017
Treatment Median Time to Second Tumor p value
Control 73.5 days -
Resveratrol 99 days 0.014
EGCG 62 days 0.239
Treatment Median Time to Third Tumor p value
Control 81.5 days -
Resveratrol 116.5 days 0.009
EGCG 85.5 days 0.309
Female offspring of Sprague-Dawley CD rats were exposed to resveratrol (1 g/kg AIN-76A diet), EGCG (0.065% in drinking water), or AIN-76A 
alone as the control diet starting at birth and continued throughout life. Each group contained a minimum of 30 rats. DMBA was administered at 60 
mg/kg body weight at 50 days postpartum. The rats were palpated for tumors twice per week and the day of each tumor appearance was recorded. 
All p values are measured against the control group.
Tumor multiplicity in female Sprague-Dawley CD rats  exposed to resveratrol, EGCG, or AIN-76A (control) from  birth until sacrifice Figure 1
Tumor multiplicity in female Sprague-Dawley CD 
rats exposed to resveratrol, EGCG, or AIN-76A 
(control) from birth until sacrifice. On day 50 postpar-
tum, all animals were treated with 60 mg DMBA/kg body 
weight. Figure 1 shows tumor multiplicity, with the values 
representing mean tumors per rat ± 2 standard errors. A p 
value < 0.05 was considered statistically significant.
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Tumor latency (2A, B, C) in female Sprague-Dawley CD rats exposed to resveratrol, EGCG, or AIN-76A (control) from birth  until sacrifice Figure 2
Tumor latency (2A, B, C) in female Sprague-Dawley CD rats exposed to resveratrol, EGCG, or AIN-76A (con-
trol) from birth until sacrifice. On day 50 postpartum, all animals were treated with 60 mg DMBA/kg body weight. Figures 
2A, 2B, and 2C depict the time to first tumor, second tumor, and third tumor (latency), respectively. A p value < 0.05 was con-
sidered statistically significant.
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least differentiated terminal ductal structures in the mam-
mary gland and reported to be the most susceptible to car-
cinogen exposure [13]. Reduction in the number of
terminal end buds has been correlated with a reduction in
tumor multiplicity in rats exposed prepubertally to the
phytoestrogen genistein [2-4]. The animals exposed to res-
veratrol throughout life had slightly, though significantly,
more combined lobule structures at 50 days post-partum.
Lobules types I and II are the most differentiated struc-
tures and this increase in gland maturation can help to
explain the protective effects seen with exposure to resver-
atrol via the diet. Chemoprevention experiments in our
lab with the phytoestrogen genistein, a component of soy,
have shown a reduction in mammary tumor multiplicity
correlated with fewer terminal end buds and increased
lobules at 50 days postpartum [2-4]. Hilakivi-Clarke et al.
also showed that the mammary glands of rats treated with
high n-3 polyunsaturated fatty acids have more lobules
and are less susceptible to carcinogen insult [24]. Thus,
enhanced maturation of the mammary gland can protect
against carcinogen insult. EGCG-treated animals showed
no increase in lobule structures and no decrease in the
number of terminal end buds, which could influence the
lack of protection against carcinogenesis.
Cell proliferation
Cellular proliferation in susceptible tissue structures is
extremely important in the oncogenic-response to carcin-
ogens. Russo et al. have shown a greater oncogenic
response in active, dividing cells in the mammary gland of
rats, with the active cells in the terminal end buds being
the most responsible for subsequent, DMBA-induced ade-
nocarcinomas [13,25-27]. In our work, at 50 days post-
partum, resveratrol-treated rats showed a significant
reduction in the percentage of proliferating cells in the
mammary terminal end buds as well as in terminal ducts
and lobules. This reduction in proliferative cells in the ter-
minal ductal structures of the mammary gland could con-
tribute to the protective effect against mammary
carcinogenesis. On the other hand, the labeling index for
EGCG-treated rats in all terminal ductal structures was not
statistically different than the control rats. No reduction of
cell proliferation at 50 days postpartum could help to
explain the lack of mammary cancer suppression observed
with EGCG as compared to resveratrol.
Apoptosis
The apoptotic labeling index for epithelial cells in mam-
mary terminal end buds in the resveratrol-treated animals
was increased 25% compared to the control rats. Though
a modest increase, the increase in apoptosis reached statis-
tical significance. The rats treated with EGCG showed no
statistical difference in apoptotic index in the mammary
terminal end buds compared the control animals. Neither
treatment affected the apoptotic index for mammary lob-
ular structures. Resveratrol has been reported to induce
apoptosis in a number of cancer cell lines, including
breast carcinoma cell lines [reviewed in [6]]. This increase
in mammary epithelial cell apoptosis in the terminal end
buds after resveratrol treatment, coupled with the signifi-
cant reduction in cell proliferation could create an envi-
ronment in the mammary gland that is less susceptible to
chemical carcinogenesis.
Table 4: Cell proliferation in mammary terminal ductal structures of 50-day-old rats exposed to resveratrol or EGCG.
Treatment Terminal End Buds Terminal Ducts Lobules
Control 4.83 ± 0.61 5.03 ± 1.07 1.75 ± 0.22
Resveratrol 2.50 ± 0.75A 0.79 ± 0.27A 0.90 ± 0.14A
ECGC 4.56 ± 0.31 4.54 ± 0.97 2.15 ± 0.31
Female Sprague-Dawley CD rats were exposed from birth to 50 days postpartum to: resveratrol (1 g/kg diet), EGCG (0.065% in water), or AIN-
76A as the control. Two hours prior to sacrifice the rats were injected with 100 mg BrdU/kg body weight. The labeling index was determined in 
three of each type of terminal structure (terminal ducts, terminal end buds, lobules) per mammary gland. A minimum of 7 rats was used in each 
group. Values represent means ± SEM. A represents a p value < 0.05.
Table 3: Terminal ductal structures in mammary glands of female rats exposed to resveratrol or EGCG in the diet.
Treatment Terminal Ducts Terminal End Buds Lobules Type I Lobules Type II Lobules Type I and 
II
Control 4 4  ±  55 3  ±  33 2  ±  31 3  ±  24 4  ±  4
Resveratrol 41 ± 6 58 ± 3 42 ± 3 15 ± 3 59 ± 5A
EGCG 28 ± 3A 39 ± 9 34 ± 4 16 ± 2 50 ± 4
Female offspring of Sprague-Dawley CD rats were exposed to resveratrol at 1 g/kg AIN-76A diet, 0.065% EGCG in the drinking water, or AIN-76A 
diet alone from birth to 50 days postpartum. The fourth abdominal mammary gland was measured in a minimum of seven rats per group. Values for 
terminal ductal structures represent means ± SEM. A represents a p value < 0.05. The p value is compared to the control group.Journal of Carcinogenesis 2006, 5:15 http://www.carcinogenesis.com/content/5/1/15
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Serum polyphenol concentrations
Bioavailability is an important consideration when deal-
ing with chemopreventive agents that are consumed in
the diet. There are multiple reports that have measured the
serum polyphenol concentrations in humans and rodents
of both resveratrol and EGCG. At the present dose of res-
veratrol given in the diet, 1 g/kg diet, a 200 gram rat that
consumed 20 grams of diet would receive ~100 mg resver-
atrol/kg body weight. The total resveratrol concentration
measured in the serum of these resveratrol treated rats was
2.00 ± 0.64 μM. Crowell et al. administered 300 mg resver-
atrol/kg body weight/day by gavage and reported a serum
concentration of 1.46 μM [28]. Resveratrol treatment,
administered via gavage to rats at 20 and 50 mg/kg body
weight respectively [29,30], gave maximum serum con-
centrations in the low micromolar range, consistent with
our results. Our results were also similar to the total serum
concentrations of resveratrol in humans (12 healthy
males) receiving 0.36 mg resveratrol/kg body weight dis-
solved in white wine [31]. This dose is about 20 times
higher than the amount of resveratrol one could receive
after moderate wine consumption. Interestingly, Gescher
and Steward point out in a commentary that low doses of
resveratrol, and thus low resveratrol serum concentra-
tions, may suffice to exert a potent chemopreventive effect
[32]. Further studies are necessary to discern the effects of
lower doses of resveratrol on mammary carcinogenesis.
In our study with EGCG, female rats received 0.065%
EGCG in the drinking water, made fresh each afternoon.
Thus, a 200 g female consuming 25 mL of fluid would
receive 16.25 mg EGCG per day (81 mg EGCG/kg body
weight). Again, this dose was extrapolated from the work
of Gupta et al. who showed that a 0.1% enriched fraction
of green tea polyphenols (62% EGCG) could inhibit pros-
tate cancer in the TRAMP mouse model [12]. That report
also stated that the dose "mimics an approximate con-
sumption of six cups of green tea per day by an average
adult human." At the dose administered, the total EGCG
concentration found in the serum was 31.06 ± 3.05 nM.
This is similar to the work of Chen et al. who treated male
rats with 75 mg EGCG/kg body weight by gavage and
reported a serum concentration of total EGCG at 43 nM
[21]. Several human studies have employed doses of
EGCG that would be equivalent to ~2–3 cups of green tea
for an average human. Lee et al. administered 20 mg green
tea solids/kg body weight and reported a maximum serum
EGCG concentration of 172 nM [33]. Another group
using a similar dose reported a maximum serum concen-
tration of total EGCG at ~720 nM [34]. Species differences
could account for the lower serum concentrations of
EGCG observed in the rat. It has been reported that most
of the EGCG does not get into the blood, but is excreted
through the bile to the colon [21]. Also, higher serum con-
centrations of EGCG have been reported when green tea
polyphenol mixtures have been administered as opposed
to pure EGCG [21]. The low circulating polyphenol con-
centration of EGCG could play a role in the lack of effect
observed on tumor multiplicity and latency observed in
this study.
Table 6: Serum concentrations of 17β-estradiol, progesterone, and prolactin in 50-day-old female rats, exposed to resveratrol or 
EGCG.
Treatment 17β-Estradiol (pg/ml) Progesterone (ng/ml) Prolactin (ng/ml)
Control 11.39 ± 4.56 12.42 ± 2.70 1.25 ± 0.10
Resveratrol 13.87 ± 2.28 14.98 ± 2.73 1.19 ± 0.04
EGCG 5.90 ± 1.64 9.64 ± 1.45 1.24 ± 0.06
Female Sprague-Dawley CD rats were exposed from birth to 50 days postpartum to: resveratrol (1 g/kg diet), EGCG (0.065% in water), or AIN-
76A as the control. Blood was collected from female rats determined to be in the estrous phase of the estrous cycle (8/group). 17β-estradiol, 
progesterone, and prolactin concentrations were measured by radioimmunoassay. Values represent the mean ± SEM.
Table 5: Apoptotic index for epithelial cells in mammary terminal ductal structures of rats 50 days postpartum exposed to resveratrol 
or EGCG.
Treatment Terminal End Buds Lobules
Control 35.43 ± 1.37 39.39 ± 2.67
Resveratrol 44.18 ± 1.84A 41.24 ± 2.38
Control 46.10 ± 1.82 43.91 ± 1.97
EGCG 49.31 ± 1.57 43.80 ± 2.52
Female Sprague-Dawley rats were exposed to resveratrol or EGCG in the diet from birth until 50 days postpartum. Apoptotic indices (positively 
stained cells/total cells) were determined from mammary epithelial cells from terminal end buds and lobule structures, with at least 7 animals per 
group. Values represent mean ± SEM. A represents a p value < 0.05.Journal of Carcinogenesis 2006, 5:15 http://www.carcinogenesis.com/content/5/1/15
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Serum 17β-estradiol, progesterone, and prolactin 
concentrations
At 50 days postpartum, resveratrol in the diet or EGCG in
the drinking water did not significantly influence the
serum concentrations of estradiol, progesterone, or prol-
actin. The serum concentrations of estradiol for control,
resveratrol-, and EGCG-treated animals were 11.4, 13.9,
and 5.9 pg/ml, respectively. Lamartiniere et al. have
reported similar serum estradiol concentrations (~10–12
pg/ml) after dietary treatment with AIN-76A or 250 mg
daidzein/kg diet [35]. The same report showed serum pro-
gesterone concentrations in the low ng/ml range, very
similar to what we saw with serum progesterone concen-
trations after resveratrol or EGCG treatment. Though not
reaching statistical significance, EGCG tended to lower
serum estradiol concentrations as compared to the control
rats (5.90 ± 1.64 versus 11.39 ± 4.56 nM). This is in line
with the previous reports of Kao et al. [36] and Hangata et
al. [37] who showed in rats and humans, respectively that
green tea treatment could lower serum estradiol concen-
trations. Serum prolactin was not significantly altered by
treatment with resveratrol or EGCG. This is consistent
with Okazaki et al., who reported no difference in serum
prolactin levels after exposure to the polyphenol genistein
[38].
Summary
Our work supports the previous reports that resveratrol in
the diet is effective at inhibiting DMBA-induced mam-
mary cancer. We have shown that resveratrol can enhance
maturation of the mammary gland as well as reduce cellu-
lar proliferation and increase apoptosis in mammary epi-
thelial cells, in a manner that is protective against
mammary carcinogenesis. Coupling this with our previ-
ous work with genistein [2-4], we plan to use a combina-
tion of genistein and resveratrol in the diet to determine
whether there is an additive or synergistic effect of these
natural polyphenols to suppress mammary carcinogene-
sis. As for the administration of EGCG in the drinking
water, no mammary protective effect was demonstrated. It
remains to be seen whether a higher dose, different route
of administration, a different tea catechin, or a mixture of
green tea catechins can protect against mammary cancer.
There is still much that remains unknown about the in
vivo molecular mechanisms of resveratrol and EGCG that
play a role in their effects on mammary carcinogenesis.
The effects on estrogen receptor pathways as well as other
steroid and growth factor pathways and effects on
enzymes that are important in the activation or removal of
xenobiotics must be elucidated such that these polyphe-
nols can be recommended for clinical trials and help in
the prevention of breast cancer.
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